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Abstract
Background: We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification
of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune response to
MUC1 tumor antigen, we have tested the efficacy of tumor irradiation combined with an MVA-MUC1-IL2 cancer vaccine
(Transgene TG4010) for murine renal adenocarcinoma (Renca) cells transfected with MUC1.
Methods: Established subcutaneous Renca-MUC1 tumors were treated with 8 Gy radiation on day 11 and
peritumoral injections of MVA-MUC1-IL2 vector on day 12 and 17, or using a reverse sequence of vaccine
followed by radiation. Growth delays were monitored by tumor measurements and histological responses were
evaluated by immunohistochemistry. Specific immunity was assessed by challenge with Renca-MUC1 cells.
Generation of tumor-specific T cells was detected by IFN-γ production from splenocytes stimulated in vitro with
tumor lysates using ELISPOT assays.
Results: Tumor growth delays observed by tumor irradiation combined with MVA-MUC1-IL-2 vaccine were
significantly more prolonged than those observed by vaccine, radiation, or radiation with MVA empty vector.
The sequence of cancer vaccine followed by radiation two days later resulted in 55–58% complete responders
and 60% mouse long-term survival. This sequence was more effective than that of radiation followed by vaccine
leading to 24–30% complete responders and 30% mouse survival. Responding mice were immune to challenge
with Renca-MUC1 cells, indicating the induction of specific tumor immunity. Histology studies of regressing
tumors at 1 week after therapy, revealed extensive tumor destruction and a heavy infiltration of CD45+ leukocytes
including F4/80+ macrophages, CD8+ cytotoxic T cells and CD4+ helper T cells. The generation of tumor-specific
T cells by combined therapy was confirmed by IFN-γ secretion in tumor-stimulated splenocytes. An abscopal
effect was measured by rejection of an untreated tumor on the contralateral flank to the tumor treated with
radiation and vaccine.
Conclusions: These findings suggest that cancer vaccine given prior to local tumor irradiation augments an
immune response targeted at tumor antigens that results in specific anti-tumor immunity. These findings support
further exploration of the combination of radiotherapy with cancer vaccines for the treatment of cancer.
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Background
Radiotherapy is a conventional modality for solid cancers
that can achieve considerable tumor debulking, however,
tumors recur locally due to radioresistance, resulting in
cancer progression. Several clinical trials based on im-
munotherapy approaches to induce an anti-tumor immune
response were not effective for advanced metastatic and
bulky disease and were compromised by tumor-induced
immunosuppression. A strategy which is currently under
extensive investigation is to combine immunotherapy/can-
cer vaccines with radiotherapy to enhance both a local and
systemic anti-tumor immune response [1–5]. The rationale
is to reduce large tumor burdens localized in the primary
tumor by radiation and eradicate local residual tumor and
metastases by inducing anti-tumor immune responses with
cytokine gene therapy, cancer vaccines, or immune check-
point inhibitors [1, 2].
We previously demonstrated that tumor irradiation
potentiates cancer vaccines based on in situ genetic
modification of tumor cells in Renca renal adenocarcin-
oma and RM-9 prostate carcinoma syngeneic murine
tumor models [6–9]. Renca tumor irradiation combined
with intratumoral IL-2 cytokine adenovector gene ther-
apy caused increased tumor destruction and infiltration
of immune cells resulting in complete responses in 40–
90% of the mice [6]. This combined therapy was more
effective than radiation or gene therapy alone and
induced specific cytotoxic T cell activity and specific
tumor immunity [6]. In other studies, we also showed
that tumor irradiation enhanced gene therapy using
plasmids to convert tumor cells into a cancer vaccine
[7–9]. Irradiation of the tumor nodule on the day
preceding initiation of gene therapy showed 50% of mice
with complete regression and induction of tumor-
specific immunity [7]. Both CD4+ helper T cells and
CD8+ cytotoxic T cells were essential for induction of an
anti-tumor immune response as demonstrated by in vivo
depletion of these subsets [9].
Recently, mechanistic studies on the role of radiation
to enhance immunotherapy gave further insights into
immune modulation of the tumor microenvironment
(TME) by radiation including inflammatory responses,
destruction of tumor cells, disruption of stroma and
vasculature [1, 2, 10–12]. Radiation-induced changes in
TME elicit in situ vaccination by causing immunogenic
cell death through release of factors from dying tumor
cells including HMGB1 [13], ATP [14], calreticulin [15],
complement [16], and tumor associated antigen (TAA),
which activate TAA presentation by dendritic cells (DC)
and priming of tumor specific CD8+ cytotoxic T lym-
phocytes (CTLs) [1, 2, 10, 17–19]. Radiation also causes
local inflammation and release of cytokines, including
IL-1, TNF-α, IFN-β, IFN-γ, and chemokines, which
facilitate activation of the anti-tumor immune response
[18, 20, 21]. However, radiation could also cause
immunosuppression by increasing regulatory T cells,
PD-L1 and tumor associated M2 macrophages, which
secrete IL-10 and TGF-β [22–26]. These suppressive
effects could be responsible for the lack of specific and
lasting anti-tumor immune response when radiotherapy
is administered alone. To target immune suppression
and enhance immune responses against the tumor, the
immunomodulatory effects of radiation could be
exploited by giving radiotherapy in conjunction with
cancer vaccines.
Our previous studies of immunotherapy and radiation
demonstrated an increased immune response directed
against the tumor cells, but the targeted TAA were
unknown [6–9]. We have now investigated whether
tumor irradiation augments a specific immune response
to MUC1 TAA antigen [27]. MUC1 is a large mucin
glycoprotein normally expressed at the luminal surface
of glandular epithelia and functions to lubricate and
protect epithelial cells. In carcinomas, MUC1 is over-
expressed, with aberrant glycosylation profile and
localization. Its overexpression in metastatic renal cell
carcinoma (RCC) and prostate carcinoma is associated
with poor prognosis, therefore MUC1 has been used in
different types of cancer vaccines [27–30]. It is note-
worthy that MUC1 was ranked second out of 75 in a
priority ranking of cancer antigens from the National
Cancer Institute [31]. TG4010 is a cancer vaccine con-
struct consisting of a recombinant, highly attenuated
modified vaccinia Ankara (MVA) virus strain expressing
both the human MUC1 and IL-2 genes (MVA-MUC1-
IL-2) [27, 32, 33]. Initial clinical Phase I and II trials
using TG4010 administered subcutaneously to prostate
cancer patients showed its safety and induction of
specific CD8+ T cells, and even stabilization of the
disease in some patients [34–36]. Therapy was well
tolerated with mostly grade 1 and 2 adverse events
including local injection site reactions, fatigue and flu-
like syndrome [36]. In metastatic RCC, treatment with
TG4010 followed by IL-2 and IFN- α2a cytokines also
showed stable disease in 30% of the patients and specific
immune responses measured in patient’s CD4+ and CD8
+ T cells [37]. Phase II trials of TG4010 in combination
with chemotherapy for advanced stages of non-small cell
lung cancer (NSCLC) demonstrated promising response
rates and survival data [38–40]. Although this vaccine
could induce immune responses and stabilization of
disease in some of the patients, additional approaches to
enhance its efficacy are needed.
To enhance the therapeutic effect of TG4010, i.e.,
MVA-MUC1-IL-2 cancer vaccine, we have tested the
efficacy of tumor irradiation for the treatment of Renca
murine RCC cells transfected with MUC1. We showed
that only the combination of MVA-MUC1-IL-2 and
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tumor irradiation resulted in complete responders and
induction of tumor specific immunity. This was not
achieved by treatment with either modality alone. We
demonstrated that administration of vaccine prior to ra-
diation was a more effective sequence than the reverse
sequence.
Methods
Tumor model
Renca is a murine RCC line of spontaneous origin in a
BALB/c mouse which is maintained in vivo by serial in-
traperitoneal (i.p.) or subcutaneous (s.c.) passages [6].
Renca cells were transfected with a plasmid coding for
human MUC1 and a stable Renca-MUC1 cell line was
generated. Expression of MUC1 was tested by immuno-
fluorescence using anti-human MUC1 antibody (clone
S.854.6, Thermo Fisher) followed by labeling with goat
anti-mouse IgG conjugated to Alexa Fluor 488. Cells
were analyzed by flow cytometry [41] and showed 96.5%
MUC1 positive cells in the Renca-MUC1 line, compared
to 1.84% positive cells in the original Renca cells (data
not shown). Renca-MUC1 cells were cultured in vitro in
DMEM medium in the presence of hygromycin B for
selection of stably transfected cells. For in vivo implant-
ation, Renca-MUC1 cells were washed in PBS and injected
s.c. in the right flank at 3x105 cells in 0.05 ml PBS, in 4–6
week old female BALB/c mice (Harlan Sprague Dawley
Inc, Indianapolis, IN). Mice were housed and handled in
facilities accredited by the American Association for the
Accreditation of Laboratory Animal Care. The animal
protocol was approved by Wayne State University Animal
Investigation Committee.
Vaccine production
TG4010 (Transgene, SA) is a suspension of MVA–MUC1–
IL-2 vector particles consisting of a recombinant, attenu-
ated, Modified Vaccinia Ankara (MVA) virus containing
the coding sequence for human MUC1 and IL-2. The
MVA–MUC1–IL-2 vector (MVATG9931) was generated
by homologous recombination in a subclone of MVA
named N33 using transfer plasmid pTG9931, which carried
the genes for MUC1 and IL-2 and flanking sequences
surrounding Deletion II of MVA. MVA–MUC1–IL-2 was
produced on primary chicken embryo fibroblasts. As an
internal negative control, an empty MVA vector
(MVATGN33.1) was used. The vectors were diluted in S08
buffer consisting of 10 mM Tris/HCl, 5% sucrose (w/v),
10 mM sodium glutamate, 50 mM NaCl (pH 8).
Radiation
Photon irradiation was delivered at a single dose of 8 Gy
to s.c. tumors located on the right flank. Three anesthe-
tized mice, in jigs, were positioned under a 6.4 mm lead
shield with 3 cut-outs in an aluminum frame mounted
on the X-ray machine to permit selective irradiation of
the right flank in 3 mice at a time [41]. The dose rate
was 58 cGy/min and first HVL is 2.68 mm Cu. Photon
irradiation was performed with a PANTAC Bipolar
Series 2 HF 300 (Test Equipment Distributors, LLC) op-
erated at 250 kV, 10 mA with 0.5 mm tin + 0.25 mm
copper + 1 mm aluminum filter at a 42.0 cm target to
mouse distance.
Tumor treatment with vaccine and/or radiation
Mice were treated with radiation and vaccine when
Renca-MUC1 tumors reached a size between 0.3x0.4 cm
and 0.3x0.5 cm, i.e., a volume of 13–15 mm3. Established
tumors were irradiated at 8 Gy photons on day 11
(Fig. 1a). A day later, peritumoral injections of vaccine
MVA–MUC1–IL-2 or MVA empty vectors were initi-
ated using a concentration of 107 PFU in 25 μl S08 buf-
fer. A second injection of vaccine was given 5 days later,
i.e., on day 17 (Fig. 1a). Experimental groups consisted
of 7–9 mice/group. Mice were monitored for tumor
growth and survival. Tumors were measured with a cali-
per in three dimensions, 3 times a week. Tumor volume
was calculated using the formula: 0.5236 x length x
width x height. When tumors reached 1.5 cm in greatest
diameter or 1 cm with ulceration, mice were sacrificed
in accordance with animal facilities regulations.
Histology and immunohistochemistry
Tumors were resected, fixed in 10% buffered formalin,
embedded in paraffin, sectioned and processed for stain-
ing with H&E. Tumor sections were stained by immuno-
histochemistry. Sections were blocked with IHC Tek
Antibody Diluent, and then incubated with primary
purified monoclonal antibodies (Abs) directed against
CD45, CD4, CD8 and F4/80 (eBiosciences, San Diego,
CA) followed by biotinylated secondary Abs (1:300) [41].
Staining was amplified with the avidin-biotin system
immunoperoxidase technique. Tumors were examined
on a Nikon E800 microscope.
Evaluation of IFN-γ secreting T cells
To determine whether radiation and vaccine induce
tumor specific T cells, splenocytes were stimulated
with Renca-MUC1 lysates in plates coated with anti-
mouse IFN-γ Ab. Tumor lysates were obtained by
3 cycles of thawing and freezing of Renca-MUC1 cells
at 37oC and –80oC, and lysate was separated by cen-
trifugation at 3,000 rpm for 5 min at 4oC. Splenocytes
were isolated from mice treated with vaccines and/or
radiation following challenge with Renca-MUC1 cells.
Splenocytes, at 106 cells/100 μl, were stimulated with
10 μg/100 μl tumor lysates in 96 well microplates
pre-coated with anti-mouse IFN-γ Ab. Cells were in-
cubated for 48 h at 37oC (5% CO2 incubator). Plates
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were, then, processed for detection of secreted IFN-γ
using a mouse IFN-γ ELISPOT kit (eBiosciences, San
Diego, CA) according to manufacturer’s instructions.
The number of spots was counted using the Immuno-
Spot Analyzer from CTL Analyzers, LLC (Shaker
Heights, OH).
Statistical analysis
Mean tumor volumes at defined times were analyzed
with the GraphPad Prism Software (Version 6.07)
using the Kruskall-Wallis test for all the treatments.
A significant difference between all treatments (P <
0.05) was followed by pairwise comparisons using the
Dunn’s multiple comparison test. Survival was ana-
lyzed using the Log-rank (Mantel-Cox) test with
GraphPad Prism Software (Version 6.07). A significant
difference between all treatments (P < 0.05) was
followed by pairwise comparisons using the Log-rank
(Mantel-Cox) test.
Results
Enhanced tumor growth inhibition by tumor irradiation
and vaccine
In pilot experiments, titration experiments using radi-
ation doses of 5 and 8 Gy and MVA-MUC1-IL-2 vaccine
doses of 105, 106 and 107 PFU showed that the combin-
ation of 8 Gy tumor irradiation with 107 PFU MVA-
MUC1-IL-2 was the most effective for the treatment of
Renca-MUC1 s.c. tumors (Additional file 1: Figure S1
and Additional file 2: Figure S2). Whereas 5 Gy radiation
alone or combined with vaccine did not cause tumor
growth inhibition, tumor growth delays were observed at
8 Gy (Additional file 1: Figure S1). Combination of 8 Gy
with vaccine doses of 106 and 107 PFU led to complete
responders (Additional file 1: Figure S1, Additional file
2: Figure S2). Therefore, doses of 8 Gy radiation and 107
PFU vaccine were selected to investigate the effect of
single and combined therapies. Established Renca-
MUC1 s.c. tumors were treated with radiation, MVA-
MUC1-IL-2 vector (vaccine), MVA-empty vector or
Renca-MUC1 
s.c. injection
D11D0
8 Gy Rad
D12
Vaccine
D17
Vaccine
a
b
Fig. 1 Growth curves of Renca-MUC1 tumors treated with tumor irradiation and vaccine. Established Renca-MUC1 tumors were untreated (Control) or
treated with MVA-empty (Empty Vector), MVA-MUC1-IL-2 vector (Vaccine), with or without radiation (Rad). Radiation was administered at 8 Gy photons on
day 11. Two peritumoral injections of vectors were administered on days 11 and 17, at 107 PFU in 25 μl S08 buffer. a. Schedule of treatment. b.
Tumor growth curves. Each symbol represents the mean tumor volume of 7-9 mice per group ± SEM at different time points post cell injection.
Data were compiled from two experiments
Hillman et al. Journal for ImmunoTherapy of Cancer  (2017) 5:4 Page 4 of 13
combined treatments of radiation with the vectors
(Fig. 1). Radiation was administered at 8 Gy photons on
day 11 and two peritumoral injections of vectors were
administered on days 11 and 17, at 107 PFU as shown in
Fig. 1a. Treatment with vaccine only or empty vector
slowed down tumor growth compared to control tumors
treated with vehicle (Fig. 1b, p > 0.05; Additional file 2:
Figure S2). Radiation alone or radiation combined with
empty vector caused tumor growth delays for about
2 weeks, and then tumor regrowth occurred (Fig. 1b,
Additional file 2: Figure S2). A greater inhibition of
tumor growth was observed by combining tumor irradi-
ation with the vaccine compared to radiation alone or
the vaccine alone (Fig. 1b, p < 0.05; Additional file 2:
Figure S2). It should be noted that distant s.c. delivery of
the vaccine to the flank opposite to the tumor did not
synergize with tumor irradiation in contrast to peritu-
moral injection.
Sequence of vaccine and radiation for the treatment of
Renca-MUC1 tumors
We have shown that tumor irradiation given one day
prior to vaccine treatment resulted in increased inhib-
ition of tumor growth (Fig. 1). To investigate the se-
quence of combined therapies and its effect on tumor
response, two different sequences consisting of radiation
first followed by vaccine and vaccine first followed by
radiation were compared in the same experiment using
8 Gy radiation and peritumoral vaccine injections at 1
x107 PFU (Fig. 2a). In the first schedule of the sequence
of radiation followed by vaccine, tumors were irradiated
on day 11, followed by vaccine administrations on day
12 and 17 (Fig. 2a). In the second schedule of the se-
quence of vaccine followed by radiation, tumors were
first injected with vaccine on day 9, then were irradiated
two days later on day 11, followed by a second treatment
of vaccine on day 17 (Fig. 2a). Based on tumor size, the
day 11 time point was selected in schedule 1 and sched-
ule 2 as a radiation time point to keep consistency with
tumor size to be irradiated (minimal differences were
observed in tumor growth within the 2 day interval).
Control tumors showed a rapid growth (Fig. 2B1).
Treatment with radiation alone showed tumor growth
delays but most of the tumors started growing again
by 1–2 weeks after radiation with only 1 mouse out
of 18 (5% responders) showing a continued tumor re-
sponse (Fig. 2B2, p > 0.05). The sequence of radiation
followed by vaccine caused tumor growth delays in all
mice up to day 25, then varied tumor growth kinetics
were observed with a marked tumor inhibition in 5
mice out of 18 (27% responders) (Fig. 2B3, p < 0.05
compared to control or radiation). The sequence of
vaccine followed by radiation also showed significant
tumor growth delays (p < 0.05 compared to control or
radiation), and the tumor regressed in 10 mice out of
18 (55% responders) (Fig. 2B4).
In a separate and identical experiment aimed at
following mouse long-term survival, established Renca-
MUC1 tumors were treated with 8 Gy radiation and
MVA-MUC1-IL-2 vector using either the schedule of ra-
diation followed by two vaccine treatments (Fig. 2a,
Schedule 1) or the schedule of vaccine followed by radi-
ation and a second vaccine treatment (Fig. 2a, Schedule
2). Follow-up of mouse survival showed that all mice in
the control group were dead by day 35 (Fig. 2c). Radi-
ation alone caused an increase in median survival to
42 days compared to 32 days in control mice (Fig. 2c, p
< 0.01). The sequence of radiation followed by vaccine
caused a further increase in median survival to 52 days
compared to radiation or control mice (p < 0.01), result-
ing in 30% overall survival by day 70 (Fig. 2c). The
reverse sequence of vaccine followed by radiation was
more effective with 60% mouse survival by day 70
(Fig. 2c, p < 0.01). The mouse survival corroborates the
findings of tumor growth depicted in Fig. 2b. These data
indicate that the sequence of vaccine followed by radi-
ation elicits a more effective anti-tumor response com-
pared to the sequence of radiation followed by vaccine.
Histology and immune cell infiltration in Renca-MUC1
tumors treated with radiation and vaccine
Tumors obtained at day 24, 1 week after the last vaccine
treatment from the experiment described in Fig. 2, were
processed for histological H&E staining or immuno-
histochemistry for immune cells. Untreated Renca
tumors presented as large vascularized nodules consist-
ing of sheets of pleomorphic epithelial cells with large
nuclei, prominent nucleoli and frequent mitosis (Fig. 3,
H&E). These tumors showed isolated F4/80+ macro-
phages and minimal infiltration by CD45+ leukocytes,
CD4+ TH cells, and CD8
+ CTL (Fig. 3 and 4, Table 1).
Tumors treated with vaccine alone exhibited focal areas
of tumor destruction with leukocyte infiltrate (data not
shown). Radiation-treated tumors showed areas of
tumor necrosis with tumor debris and remaining tumor
areas with multiple abnormal degenerating large giant
cells containing large vacuoles and several nuclei (Fig. 3,
H&E). Eccentric and pyknotic nuclei were seen in giant
cells, which are characteristic of the effect of radiation
on tumor cells, causing defective mitosis and cytokinesis,
as previously described [6]. Focal infiltration of immune
cells was seen in these tumors (Fig. 4, Table 1). In
contrast, tumors treated with combined radiation and
vaccine showed extensive tumor destruction with large
areas of necrosis and hemorrhages (Fig. 3, H&E). A few
remaining giant tumor cells were observed but a marked
overall decrease in cellularity was prominent (Fig. 3,
H&E). These tumors were heavily infiltrated by F4/80+
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Schedule 2: Sequence of vaccine followed by radiation
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Fig. 2 (See legend on next page.)
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macrophages (Fig. 3, Table 1) and CD45+ leukocytes
consisting of T cells positive for CD4 TH and CD8 CTLs
markers (Fig. 4, Table 1). The extent of tumor destruc-
tion and immune infiltration was greater with the se-
quence of vaccine followed by radiation than radiation
followed by vaccine (Figs. 3 and 4).
Anti-tumor response and specific immunity to tumor
rechallenge
The responses of mice treated with vaccine and radiation
obtained from 3 independent experiments are summa-
rized in Table 2. No responders were observed in control
mice and in mice treated with vaccine only. In radiation-
treated mice, only 4% of mice showed complete regres-
sion. Six radiation-treated surviving mice, including two
cured mice and 4 mice still bearing tumors, developed
tumors in their left flank upon challenge with Renca-
MUC1 cells, showing that radiation alone did not cause
anti-tumor immunity (Table 2). When mice were treated
with radiation and empty MVA, a few mice (3 out of 20
mice) were cured and rejected Renca-MUC1 tumor
challenge indicating some tumor immunity, probably
directed against vaccinia antigens (Table 2). Mice treated
with the sequence of radiation followed by vaccine
(Schedule 1, Fig. 2a) showed a higher cure rate (24%) and
demonstrated specific tumor immunity when rechallenged
with Renca-MUC1 (Table 2). A few responding mice
rechallenged in a different site also with Renca cells did
reject Renca, suggesting induction of immunity to Renca
TAA. In repeated experiments, treatment with the sched-
ule of vaccine followed by radiation (Schedule 2, Fig. 2a)
consistently resulted in a greater number of responders
(58%) which were immune to rechallenge with Renca-
MUC1 (Table 2).
Immunity to rechallenge with Renca-MUC1 cells
suggested the generation of specific T- cells against
tumor antigens. Therefore, we assessed the production
of IFN-γ in splenocytes isolated from mice, which were
cured by vaccine and radiation treatments and rejected
rechallenged tumor cells. Data were compared to sple-
nocytes from non-responding tumor-bearing mice.
Splenocytes from cured mice showed consistent produc-
tion of IFN-γ cytokine upon in vitro stimulation with
Renca-MUC1 cell lysates confirming that the treatment
of radiation and vaccine induced T cells specific to the
tumor cells (Table 2). Interestingly, responding mice also
showed IFN-γ cytokine upon in vitro stimulation with
Renca cell lysates, indicating the generation of T cells
specific to Renca antigens in addition to MUC1 antigen.
This might be an evidence of epitope spreading. In con-
trast, splenocytes obtained from tumor-bearing mice not
responding to treatment did not produce IFN-γ.
We designed a separate pilot experiment to probe
abscopal response (Table 3). Established primary Renca-
MUC1 tumors on the right flank were treated with vac-
cine followed by radiation (schedule 2, Fig. 2a). Early
rechallenge was given with Renca-MUC1 cells on the
contralateral left flank, at 7 days after radiation and one
day after the second vaccine treatment (Table 3). In 4 out
of 8 mice, the primary Renca-MUC1 tumor regressed on
the right flank and no growth of the challenged tumor on
the left flank was observed upon follow up for up to
70 days, when mice were killed for IFN-γ assay (Table 3).
The splenocytes from these mice produced IFN-γ cyto-
kine upon in vitro stimulation with Renca-MUC1 cell
lysates (Table 3). These data indicate that combined irradi-
ation and vaccine induced an early systemic immune anti-
tumor response, which caused an abscopal effect on a
distant tumor. Control mice or radiation-treated mice
developed both primary tumors in the right flank and
rechallenge tumors in the left flank (Table 3).
Discussion
The MVA–MUC1–IL-2 cancer vaccine construct was
successfully tested clinically in patients with MUC1-
overexpressing malignancies in order to induce a specific
anti-tumor immune response. Subcutaneous treatments
with MVA-MUC1-IL-2 were well tolerated in patients
with advanced RCC, prostate cancer, or NSCLC and were
shown to induce MUC1 specific responses in some of the
patients [34–39]. Nevertheless, clinical responses were
limited when MVA-MUC1-IL-2 was given alone as mono-
therapy or combined with cytokines or chemotherapy,
emphasizing the need to develop additional strategies to
increase its efficacy.
(See figure on previous page.)
Fig. 2 Sequence of tumor irradiation and vaccine for the treatment of Renca-MUC1 tumors. Established Renca-MUC1 tumors were treated with
8 Gy radiation (Rad) and MVA-MUC1-IL-2 vector (Vaccine) administered peritumorally at 107 PFU in 25 μl S08 buffer. a. Schedule 1: Sequence of radiation
followed by vaccine. Tumors were irradiated on day 11, followed by vaccine on day 12 and 17. Schedule 2: Sequence of vaccine followed by radiation. Tumors
were first injected with vaccine on day 9, then were irradiated two days later on day 11, followed by a second treatment of vaccine on day 17. b. Tumor
growth curves. B1. Control (Control) untreated mice. B2. Radiation treatment alone. B3. Schedule 1 sequence of radiation followed by vaccine. B4. Schedule
2 sequence of vaccine followed by radiation. Each symbol represents the tumor volume of individual mice with 8 mice per group for control and 18 mice
per treatment group B2, B3, and B4 at different time points post cell injection. c. Survival curves. In a separate experiment identical to that shown in A,
established Renca-MUC1 tumors were treated with 8 Gy radiation (Rad) and MVA-MUC1-IL-2 vector (Vaccine) administered peritumorally at 107 PFU using
either Schedule 1 of radiation followed by two vaccine treatments or Schedule 2 of vaccine followed by radiation and a second vaccine treatment. Mice
were followed for survival (n= 8 mice for control or radiation alone and n= 12 mice for combined radiation and vaccine)
Hillman et al. Journal for ImmunoTherapy of Cancer  (2017) 5:4 Page 7 of 13
Our preclinical studies demonstrate that radiation en-
hanced the efficacy of MVA-MUC1-IL-2 cancer vaccine
in a murine RCC-MUC1 transfected tumor model. Signifi-
cant tumor growth inhibition was observed using a single
high radiation dose of 8Gy and two administrations of
MVA-MUC1-IL-2 at a high dose of 107 PFU, given a week
apart. The sequence of cancer vaccine followed by
radiation two days later resulted in 55–58% complete re-
sponders in short term experiments and 60% mouse sur-
vival in a long-term experiment, showing consistency in
the response rate. This sequence was more effective than
the sequence of radiation followed a day later by cancer
vaccine leading to 24–30% complete responders and 30%
mouse survival. Responding mice which showed complete
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Fig. 3 Histology and macrophage infiltration in Renca-MUC1 tumors treated with radiation and vaccine. Established Renca-MUC1 tumors were treated
with 8 Gy radiation (Rad) and MVA-MUC1-IL-2 vector (Vaccine) administered peritumorally at 107 PFU using either Schedule 1 of radiation followed by
two vaccine treatments (Rad + Vaccine) or Schedule 2 of vaccine followed by radiation and a second vaccine treatment (Vaccine + Rad) as described in
Fig. 2. Tumors sections, obtained at one week after the last vaccine treatment, were stained for H&E or by IHC for F4/80+ macrophages. The main findings
were labeled with T for tumor, V for vessels, N for necrosis, M for mitosis, G for giant cells, H for hemorrhages and IF for inflammatory cells. In H&E stained
tumor sections, control tumors presented as sheets of pleomorphic epithelial cells with frequent mitosis and minimal immune cells infiltrates. Radiation-
treated tumors showed areas of necrosis, numerous giant cells with abnormal mitosis, eccentric nuclei or large vacuoles. Focal infiltration of immune cells
was seen. Tumors treated with radiation and vaccine showed extensive tumor destruction with large areas of necrosis and hemorrhages, a few remaining
giant tumor cells and overall decreased cellularity. Staining for F4/80+ macrophages showed few macrophages within control and radiation treated tumors
but a heavy infiltration of macrophages in radiation and vaccine treated tumors (arrows). The extent of tumor destruction and immune infiltration was
greater with Vaccine + Rad sequence than with Rad + vaccine sequence. All magnifications X40
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tumor regression were immune to challenge with Renca-
MUC1, indicating that these mice developed specific
tumor immunity. These findings are similar to other stud-
ies demonstrating 40% complete anti-tumor responses
by 8Gy tumor irradiation given in conjunction with a
complex vaccine encoding for CEA as an antigen, for
co-stimulatory molecules and GM-CSF in MC38-CEA
transfected colon adenocarcinoma in CEA transgenic
C57BL/6 mice [42]. These responses were not observed
with radiation or vaccine alone akin to our data. A few
mice treated which radiation and empty vector developed
tumor immunity, which was probably a response to
vaccinia antigens.
Extensive tumor destruction by radiation and MVA-
MUC1-IL-2 vaccine was confirmed early by histological
evaluation of regressing tumors at one week after
treatment, showing that the synergistic effect of radiation
and vaccine occurs rapidly. A massive invasion of F4/80+
macrophages, CD45 leukocytes, CD8+ CTLs and CD4+
TH cells was observed in treated tumors, in contrast to
focal staining of immune cells in radiation-treated tumors.
These immuno-histology studies showed a drastic effect
of the combined therapy on immune infiltration in the
TME and corroborated with tumor regression and devel-
opment of specific tumor immunity.
In support of these findings, the generation of specific T
cells to MUC-1 antigen by combined therapy was con-
firmed by specific IFN-γ secretion in the splenocytes from
cured mice stimulated in vitro with Renca-MUC1 lysates.
Table 1 Histological scoring of immune cell infiltrates in tumors
treated with radiation and vaccine
Control Radiation Rad + Vaccine Vaccine + Rad
F4/80+ cells + + +++ ++++
CD45+ cells + ++ ++++ ++++
CD4+TH cells ± ++ +++ ++++
CD8+ CTL cells + ++ ++++ ++++
Tumors were either treated with the sequence of radiation followed by
vaccine (Rad + Vaccine) or vaccine followed by radiation (Vaccine + Rad) as
shown in Fig. 2a. The extent of inflammatory infiltration in treated tumors,
which is presented in Figs. 3 and 4, was scaled from mild (±), moderate (+),
strong (+ +), very strong (+ + +), to heavy (+ + + +) for immune cell markers
including F4/80+ macrophages, CD45+ leukocytes, CD4+ TH cells and CD8+ CTL
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Fig. 4 Leukocyte infiltration in Renca-MUC1 tumors treated with radiation and vaccine. Tumor sections obtained from the experiment described in Fig. 3
were also stained by IHC for CD45+ leukocytes, CD4+ TH cells, and CD8
+ CTL and cells positive for these markers are shown (arrows). Control tumors
showed minimal immune cell infiltration. Radiation showed focal infiltration of CD45+, CD4+, and CD8+ cells. Following radiation and vaccine, a massive
infiltration of CD45+, CD4+, and CD8+ cells was observed in areas of tumor destruction. The extent of tumor destruction and immune infiltration was
greater with Vaccine + Rad sequence than with Rad + vaccine sequence. All magnifications X40
Hillman et al. Journal for ImmunoTherapy of Cancer  (2017) 5:4 Page 9 of 13
Stimulation with parental Renca cell lysates in this assay
also induced IFN-γ, suggesting a broader response against
other TAA on Renca due to epitope spreading. This is in
agreement with rejection of Renca cell challenge observed
in cured mice in addition to rejection of Renca-MUC1
cells. This phenomenon of antigen cascade or epitope
spreading was clearly demonstrated in other studies,
which reported immune responses against epitopes dis-
tinct from the inducing antigen and were caused by radi-
ation and cancer vaccines [42]. The complete anti-tumor
responses observed in cured mice were associated with
specific anti-tumor immunity. These data confirm that
local tumor irradiation stimulated immune events
potentiated by the cancer vaccine. These findings are in
agreement with our previous studies demonstrating in-
creased efficacy when tumor irradiation was combined
with immunotherapy either with systemic IL-2 [43, 44] or
intratumoral Ad-IL-2 in Renca tumors [6] or with plas-
mids to increase immunogenicity of RM-9 tumors [7, 9].
These responses were associated with generation of T cells
specific to the tumor and induction of specific anti-tumor
immunity, which required both CD4+ TH cells and CD8
+
CTLs [6, 9, 43]. Mechanistic studies have shown that local
tumor irradiation activated CD8+ T cells in splenocytes,
tumor-draining lymph nodes and TME [19, 45, 46].
However, radiation or immunotherapy alone were not
sufficient to induce a curative anti-tumor response,
probably as a result of immunosuppression induced in
TME either by the tumor or the radiation [3, 45].
The abscopal effect of radiotherapy causing regression
at distant metastatic sites was observed in some rare clinical
cases, presumably as the result of an anti-tumor immune
response. Recently, several pre-clinical and clinical studies
showed that addition of immunotherapy increased abscopal
responses by inducing systemic anti-tumor immunity
[3, 47–49]. Abscopal effects were observed by strategies to
improve cross-priming of anti-tumor T cells including
stimulation of DC by Flt3-Ligand [47], treatment with
GM-CSF [49, 50], DC [51], anti-PD1 [48] and anti-CTLA-4
antibodies [43, 52, 53]. In our earlier studies, the combin-
ation of systemic IL-2 with left lung irradiation at 8 Gy in a
mouse Renca lung tumor model caused a significant
abscopal response in the non-irradiated right lung [43]. In
the current study, we also demonstrated evidence of the
abscopal effect of tumor irradiation upon combination
MVA- MUC1-IL-2 vaccine.
Even though, the anti-tumor immune response medi-
ated by the combined therapy was significant in 50–60%
of the mice, tumor regrowth in non-responders could be
due to their inability to overcome immune suppression
Table 3 Abscopal effect
aResponders/Cured bImmune to
Rechallenge
cIFN-γ Mean
Spots ± SD# Mice/Total Percent
Control 0/7 0% 0/7 N/A
Radiation 0/8 0% 0/8 N/A
Vaccine + Rad (Schedule 2) 4/8 50% 4/4 147.2 ± 7.8
To test for abscopal effect, established Renca-MUC1tumors were treated either with vehicle (control), 8Gy radiation or vaccine followed by radiation (schedule 2,
Fig. 2a). aResponders/Cured: Responders were characterized by inhibition of tumor growth or complete tumor regression. bAt an early time point after treatment,
7 days after radiation and one day after the second vaccine treatment, mice were rechallenged with Renca-MUC1 cells on the contralateral left flank. cOn day 70,
the splenocytes of mice immune to rechallenge were tested in IFN-γ ELISPOT assay
Table 2 Response of Renca-MUC1 tumors to radiation and vaccine and tumor rechallenge
aResponders/Cured bImmune to
Rechallenge
cIFN-γ Mean
Spots ± SD# Mice/Total Percent
Control 0/36 0% N/A N/A
Vaccine 0/7 0% N/A N/A
Radiation 2/43 4% 0/6 N/A
Rad + Empty Vector 3/20 15% 3/3 140.4 ± 29.4
Rad + Vaccine (Schedule 1) 11/45 24% 9/9 156.4 ± 24.6
Vaccine + Rad (Schedule 2) 17/29 58% 7/8 152.6 ± 24.1
Data were compiled from three independent experiments
aResponders/Cured: Responders were characterized by inhibition of tumor growth or complete tumor regression
bImmune to rechallenge: Responding and non-responding mice were challenged with 1x105 Renca-MUC1 cells injected in the left flank contralateral to the Renca-MUC1
primary tumor on day 40–60
cIFN-γ: Splenocytes were obtained from mice at 3-4 weeks after tumor rechallenge, stimulated with Renca-MUC1 cells in vitro and tested for production of IFN-γ in
an ELISPOT assay
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in TME. This therapeutic approach could be further im-
proved by approaches to reduce immunosuppressive
mechanisms in the TME, such as targeting immune
checkpoints. Monoclonal antibodies directed against im-
mune checkpoints including CTLA-4, PD1 or PD-L1 were
found to be effective at potentiating radiotherapy, leading
to enhanced primary responses and abscopal systemic
responses in tumor models in mice [25, 48, 52, 54]. Inter-
estingly, these studies showed a decrease in CD4+CD25
+FOXP3+ immunosuppressive Tregs which was dependent
on the radiation doses.
Conclusions
Several critical issues have to be addressed when design-
ing clinical protocols of radiation and immunotherapy
including the selection of the radiation regimen and
dose, the sequence and timing of both modalities, the
frequency of administration and route of delivery of im-
munotherapy. The selection of the radiation regimen has
to be considered such as fractionated radiation at low
doses or fewer high radiation dose, as currently used in
hypofractionation [2, 55]. In our pre-clinical studies and
others, tumor irradiation with 8 Gy or doses in the range
of 6–15 Gy was synergistic with immunotherapy ap-
proaches. Intratumoral versus systemic administration of
immunotherapy has to be carefully selected depending
on the approach. While systemic injections of cytokines
and antibody therapy were found to enhance radiother-
apy, some cancer vaccines were more effective when
delivered in the tumor. The sequence of radiation and
immunotherapy may also vary depending on the im-
munotherapy approach and the timing is crucial to take
advantage of immune events triggered by each modality
without compromising an ongoing immune response by
adding either one at the wrong time, as discussed by
Kalbasi et al. [55] and Vatner et al. [2]. In the current
study, the anti-tumor response was more effective when
the cancer vaccine preceded tumor irradiation by two
days, probably by initiating immune mechanisms poten-
tiated by subsequent immunogenic cell death caused by
radiation. It should be noted that human MUC1 is a
self-molecule in human beings but an immunogenic
xeno-antigen in mice. Immune responses to a self- anti-
gen are different from those to a foreign antigen; there-
fore our findings in the MUC1 mouse model cannot
predict whether MVA- MUC1-IL-2 vaccine is a good
candidate for therapeutic combination with radiation in
cancer patients. Translation from mouse studies to hu-
man studies has to take into accounts the limitations of
the pre-clinical experimental models and can be used
only as guidance for the design of clinical protocols.
Nevertheless, further pre-clinical studies investigating
strategies to improve the combination of radiation with
immunotherapy are warranted while conducting side by
side clinical trials to address critical issues relevant for
effective application of these two modalities [2, 55].
Additional files
Additional file 1: Figure S1. Pilot experiments to determine radiation
and vaccine doses for combination treatment. Established Renca-MUC1 tu-
mors were untreated (Control) or treated with radiation at 5 or 8 Gy, or with
radiation and MVA-MUC1-IL-2 vector (Vaccine) at 105 or 106. Radiation was
administered on day 11 and two peritumoral injections of vectors were ad-
ministered on days 11 and 17. Each symbol represents the tumor volume of
individual mice for each treatment group of (n = 5–7 mice for A, B, C; n = 8-
9 mice for D, E, F) at different time points post cell injection. Data were com-
piled from two experiments. (PDF 452 kb)
Additional file 2: Figure S2. Growth curves of Renca-MUC1 tumors
treated with tumor irradiation and vaccine. Detailed tumor growth repre-
senting the tumor volume of individual mice for each treatment group
shown in Fig. 1. (PDF 458 kb)
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